Abstract
Inflammatory bowel diseases [IBD] are a heterogeneous spectrum with two extreme phenotypes, Crohn's disease [CD] and ulcerative colitis [UC], which both represent numerous phenotypical variations. Hence, we should no longer approach all IBD patients similarly, but rather aim to rethink clinical classifications and modify treatment algorithms to usher in a new era of precision medicine in IBD. This scientific ECCO workshop aims to provide a state-of-the-art overview on prognostic and predictive markers, shed light on key questions in biomarker development, propose best practices in IBD biomarker development [including trial design], and discuss the potential for multi-omic data integration to help drive further advances to make precision medicine a reality in IBD.
Author supplied keywords
Cite
CITATION STYLE
Verstockt, B., Noor, N. M., Marigorta, U. M., Pavlidis, P., Deepak, P., Ungaro, R. C., … Scharl, M. (2021). Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD-Disease Outcome and Response to Therapy. In Journal of Crohn’s and Colitis (Vol. 15, pp. 1431–1442). Oxford University Press. https://doi.org/10.1093/ecco-jcc/jjab050
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.